spacer
home > ict > summer 2016 > stronger through collaboration
PUBLICATIONS
International Clinical Trials

Stronger Through Collaboration

ICT: Can you tell us more about your recent partnership with ARISGlobal?

Anne Zielinski: Pharmacovigilance as a service, which enables sponsors to reliably outsource safety reporting, is a rapidly growing area for Bioclinica. Under this partnership, we have named ARISg from ArisGlobal as our preferred safety platform, and ArisGlobal has chosen Bioclinica as its preferred vendor for implementation and business processes consulting.

How is this initiative contributing to the eClinical environment?


We are increasingly seeing clinical trial sponsors express a preference for enabling technologies within an integrated platform as a service model. Our collaboration with ArisGlobal responds to this shift by bringing an end-to-end platform solution to the industry that minimises sponsors’ concerns as to which technologies are being used and how they are connected. The integrated Bioclinica Express electronic data capture (EDC) and ARISg offer many advantages for sponsors, including optimised processing of adverse events.

And how, in particular, is ARISGlobal’s Safety Cloud enhancing Bioclinica’s pharmacovigilance services?


Traditionally, sponsors have licensed safety systems and hosted them in their own premises − a model known as ‘on premise’. It requires sponsors to assume all responsibility for hosting and maintaining hardware, implementing upgrades and applying software patches. By comparison, ArisGlobal’s Safety Cloud allows sponsors to outsource these functions, while simultaneously achieving high availability and up-to-date regulatory compliance. Bioclinica’s safety case reporting leverages ArisGlobal Safety Cloud features.

What are the current challenges of pharmacovigilance and the eClinical landscape respectively?


Getting all clinical research systems to work together so that the end user has the experience of using a single system is a major challenge. Another hurdle is how to leverage the richness of the data that comes with predictive analytics and machine learning to extract insights for improved quality in the overall research process.

Bearing in mind the benefits of eClinical solutions, are there any disadvantages/issues that need to be considered?


Innovative eClinical solutions hold promise to yield even greater value than they do now, but sponsors’ concern over regulatory acceptance can impede adoption. Our industry will greatly benefit from sponsors and regulators working more closely to explore and implement the full capability of technologies. At the end of the day, it is about a shared goal to improve research efficiency and productivity, while protecting patients at the same time.

What is next in the pipeline?


More robust and predictive analytics incorporated in smart ways in the planning and conduct of trials; leveraging mobility to reduce subject time at the site and to enhance data comprehensiveness; and increased fluidity and ease in the user experience.

What do you think clinical trials will look like in 10 years’ time?


While clinical research will continue to be carried out rigorously, the apparent differences between clinical research and routine care will become blurred. Smaller and smaller cohorts will be analysed as more data – genotypic, phenotypic and behavioural – allow for greater population segmentation.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Anne Zielinski is responsible for Bioclinica’s App xChange, a programme offering clinical researchers and patients innovative technologies and services that complement Bioclinica eHealth offerings. A pioneer in the field, Anne brought an early EDC system to market at CB Technologies, and spent the last 10 years with Medidata, where she designed, built and grew a successful technology partner programme. She has a BS in Biology from Edgewood College, and an MBA from the Wharton School at the University of Pennsylvania.
spacer
Anne Zielinski
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Hope for a new treatment for the autoimmune neuromuscular disease Myasthenia Gravis (MG)

- The biotech companies 3P Biopharmaceuticals and Toleranzia collaborate for that MG treatment - MG is an orphan disease which has a major unmet medical need and a large market potential - The drug candidate,TOL2, has already achieved several positive preclinical results
More info >>

White Papers

Clinical Trials in Emerging Markets: Goldmines or Landmines?

Pharm-Olam, LLC

Over the past decade, biopharmaceutical companies have increasingly turned to emerging markets as a way to reduce clinical trial costs and timelines. Areas such as Eastern Europe, India, and Latin America—with their ready population of treatment naïve patients—can be an answer to the intense competition for patients seen in developed markets. Many of the countries within these regions may now be considered as “emerged” countries but yet, conducting trials in these regions does require some special attention and expertise. Before deciding to conduct studies in these areas, companies should have a full appreciation for the ethical, medical, regulatory, legal, and operational hurdles that must be surmounted for success. Here we highlight a number of those issues and offer our recommendations for how sponsor companies can deal with them effectively.
More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement